Real estate technology platform RESAAS has entered into an agreement with social-impact investment company QuestCap to sell COVID-19 antibody tests to real estate professionals across the country.
The agreement was executed on Aug. 24 with a one-year term.
The FDA-approved tests, which cost $50 each, offer results in eight minutes and are 98.9% accurate in detecting two antibodies — IgM and IgG — according to RESAAS.
IgM antibodies appear first, while the patient is still infected by the virus. IgG antibodies appear after the infection, meaning the patient has had COVID-19 previously, and they have recovered from it. At present, it’s not known conclusively how long the IgG antibodies last for because the virus is so new.
“Real estate agents today are challenged by the constraints the crisis at hand presents us all,” said RESAAS CEO Tom Rossiter in a press release. “We are proud to secure FDA-approved COVID-19 tests through our partnership with QuestCap, enabling American real estate agents and their clients to transact real estate with new levels of confidence.”
As the industry continues to face challenges during the pandemic, the COVID-19 Rapid Tests are critical in preserving and protecting market values and activity, said MedQuest Medical Advisory Committee Chairman Dr. Glenn Copeland.
“Effective screening, testing and data-gathering gives rise to both self-governance and professional empowerment so real estate professionals and their clients can re-engage in normal business activity which is critical in preserving and protecting the industry, market values and activity.”
Agents and brokerages can access the tests by emailing safety@resaas.com.